Celen, Mustafa KemalAkdemir, IremTekin, RecepBayan, KadimAyaz, Celal2024-04-242024-04-2420171307-94412147-2939https://doi.org/10.4274/vhd.10337https://hdl.handle.net/11468/19722Hepatitis C is a viral disease having a worldwide importance and posing a risk for liver complications. With the new treatment options, it is easy to manage with higher rates of success. Among them, one of the most recent one is elbasvir/grazoprevir option. This study presents the results of two treatment-naive patients treated with elbasvir/grazoprevir. The first case was a male non-cirrhotic patient and the second one was a female who suffered from compensated hepatic cirrhosis. Both patients received elbasvir/grazoprevir 50/100 mg in a single tablet for 12 weeks. Persistent viral response was achieved in both patients and no side effect was observed during the treatment. Elbasvir/grazoprevir combination, one of the recent treatments, was considered effective and tolerable.eninfo:eu-repo/semantics/openAccessHepatitis C VirusOral Antiviral TreatmentElbasvir/GrazoprevirArticle2313436WOS:00040462930000910.4274/vhd.10337N/A